3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Completed
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
1
Pathologic Processes
1
Oligodendroglioma
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Glioma
1
Disease Attributes
1
Astrocytoma
1
Interventions
Afatinib
3
niraparib
2
lenvatinib
2
ibrutinib
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Ramucirumab
2
Gefitinib
2
Capecitabine
2
Abiraterone Acetate
2
3-Iodobenzylguanidine
2
zenocutuzumab
1
vorasidenib
1
tucatinib
1
trilaciclib
1
trifluridine tipiracil drug combination
1
tovorafenib
1
talquetamab
1
tafasitamab
1
selpercatinib
1
sacituzumab govitecan
1
ripretinib
1
pralsetinib
1
ponatinib
1
pomalidomide
1
pirtobrutinib
1
pertuzumab
1
olaratumab
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
INDUSTRY
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing